Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FKC876 in Relapsed/Refractory Large B-Cell Lymphoma (Phase I/II, China, CTR20181687)
CTR20181687Phase 2Completed
- Sponsor
- Fosun Kairos
- Start
- Nov 2018
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of axicabtagene ciloleucel in diffuse large B-cell lymphoma (DLBCL), primary mediastinal large B-cell lymphoma (PMBCL), large-cell lymphoma, follicular lymphoma, transformed (t-FL), sponsored by Fosun Kairos. Started Nov 2018; status: completed.
02
Drugs
axicabtagene ciloleucel
03
Conditions
diffuse large B-cell lymphoma (DLBCL)primary mediastinal large B-cell lymphoma (PMBCL)large-cell lymphomafollicular lymphoma, transformed (t-FL)
Beyond the preview
Go deeper on CTR20181687.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20181687.